A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

开始日期2021-05-26

申办/合作机构

Caribou Biosciences, Inc.

100 项与 CB-010 相关的临床结果

登录后查看更多信息

100 项与 CB-010 相关的转化医学

登录后查看更多信息

100 项与 CB-010 相关的专利（医药）

登录后查看更多信息

项与 CB-010 相关的文献（医药）

2024-06-01·Theriogenology

A single administration of carbetocin before electroejaculation increases the insemination doses produced from each ejaculate in rams

Article

作者: Freitas-de-Melo, A ; Beracochea, F ; Ungerfeld, R ; Santiago-Moreno, J ; Orihuela, J C ; Silveira, P ; Pinto-Santini, L ; Viera, M N ; Giriboni, J

The aim of the study was to determine the effect of carbetocin administration (a long-acting analog of oxytocin) 20 or 10 min before electroejaculation (EE) on the duration of semen collection procedure, quantitative and qualitative characteristics of the ejaculate, and stress biomarkers in rams. Semen was collected from 12 Corriedale rams (age, 2.5-5.5 years old) with EE, in a Latin-square design, administrating carbetocin (0.2 mg/100 kg of body weight i.v.) 20 or 10 min before EE, or without carbetocin administration (CB-20, CB-10, and CON treatments, respectively). Each treatment was applied to different rams every 3-4 days, allowing all the rams to receive all three treatments. Carbetocin administered 20 or 10 min before EE increased the number of sperm ejaculated (P = 0.01), the semen concentration (P = 0.02), the number of insemination doses collected in a single collection (P = 0.01), and the number of insemination doses collected/electrical pulses administered (P = 0.05) compared to control rams. Carbetocin administered 20 or 10 min before semen collection prolonged the time required for EE and the number of pulses administered during EE compared to CON rams (P < 0.03 for both). The CB-10 rams required the administration of more electrical pulses during ejaculation than CON rams (P = 0.001), and CB-20 treatment tended to require more electrical pulses than CON rams (P = 0.06). The volume of the ejaculate was greater in CB-10 than in CON rams (P = 0.01), and that of CB-20 treatment tended to be greater than CON rams (P = 0.08). The percentage of sperm with intact membrane was greater in CB-20 than in CON rams (P = 0.01). Total protein, albumin, and globulin concentrations were lower immediately after carbetocin administration 20 or 10 min before EE. The treatments did not affect cortisol concentration, glycemia, rectal and surface temperatures, heart rate, and facial expressions. Carbetocin administration before EE of rams improved the quantitative and qualitative characteristics of the ejaculate, duplicating the number of insemination doses collected. It can be a promising treatment to obtain a greater quantity of doses to inseminate with a lower frequency of semen collections, reducing the negative impacts of EE on animal welfare.

2023-07-01·Cytotherapy

Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness.

Article

作者: Fowler, Tristan W. ; Williams, Carolyn ; van Overbeek, Megan ; Bryan, Mara ; Lau, Elaine ; Skoble, Justin ; Kwong, George ; Kohrs, Bryan ; Garner, Elizabeth ; Smith, Stephen C. ; Clarke, Starlynn C. ; McCawley, Shannon ; Fuller, Chris K. ; Sun, Bee-Chun ; Davis, Ryan T. ; Irby, Matthew ; Gradia, Scott ; Kanner, Steven B. ; Donohoue, Paul D. ; Lilley, Graham W. J. ; Storlie, Meghan ; Banh, Lynda ; Edwards, Leslie

BACKGROUND AIMS:

Therapeutic disruption of immune checkpoints has significantly advanced the armamentarium of approaches for treating cancer. The prominent role of the programmed death-1 (PD-1)/programmed death ligand-1 axis for downregulating T cell function offers a tractable strategy for enhancing the disease-modifying impact of CAR-T cell therapy.

METHODS:

To address checkpoint interference, primary human T cells were genome edited with a next-generation CRISPR-based platform (Cas9 chRDNA) by knockout of the PDCD1 gene encoding the PD-1 receptor. Site-specific insertion of a chimeric antigen receptor specific for CD19 into the T cell receptor alpha constant locus was implemented to drive cytotoxic activity.

RESULTS:

These allogeneic CAR-T cells (CB-010) promoted longer survival of mice in a well-established orthotopic tumor xenograft model of a B cell malignancy compared with identically engineered CAR-T cells without a PDCD1 knockout. The persistence kinetics of CB-010 cells in hematologic tissues versus CAR-T cells without PDCD1 disruption were similar, suggesting the robust initial debulking of established tumor xenografts was due to enhanced functional fitness. By single-cell RNA-Seq analyses, CB-010 cells, when compared with identically engineered CAR-T cells without a PDCD1 knockout, exhibited fewer T_reg cells, lower exhaustion phenotypes and reduced dysfunction signatures and had higher activation, glycolytic and oxidative phosphorylation signatures. Further, an enhancement of mitochondrial metabolic fitness was observed, including increased respiratory capacity, a hallmark of less differentiated T cells.

CONCLUSIONS:

Genomic PD-1 checkpoint disruption in the context of allogeneic CAR-T cell therapy may provide a compelling option for treating B lymphoid malignancies.

2023-01-01·Frontiers in network physiology

Assessing cardiorespiratory interactions via lagged joint symbolic dynamics during spontaneous and controlled breathing.

Article

作者: Cairo, Beatrice ; Bari, Vlasta ; De Maria, Beatrice ; Gelpi, Francesca ; Porta, Alberto

Introduction: Joint symbolic analysis (JSA) can be utilized to describe interactions between time series while accounting for time scales and nonlinear features. JSA is based on the computation of the rate of occurrence of joint patterns built after symbolization. Lagged JSA (LJSA) is obtained from the more classical JSA by introducing a delay/lead between patterns built over the two series and combined to form the joint scheme, thus monitoring coordinated patterns at different lags. Methods: In the present study, we applied LJSA for the assessment of cardiorespiratory coupling (CRC) from heart period (HP) variability and respiratory activity (R) in 19 healthy subjects (age: 27-35 years; 8 males, 11 females) during spontaneous breathing (SB) and controlled breathing (CB). The R rate of CB was selected to be indistinguishable from that of SB, namely, 15 breaths·minute^-1 (CB15), or slower than SB, namely, 10 breaths·minute^-1 (CB10), but in both cases, very rapid interactions between heart rate and R were known to be present. The ability of the LJSA approach to follow variations of the coupling strength was tested over a unidirectionally or bidirectionally coupled stochastic process and using surrogate data to test the null hypothesis of uncoupling. Results: We found that: i) the analysis of surrogate data proved that HP and R were significantly coupled in any experimental condition, and coupling was not more likely to occur at a specific time lag; ii) CB10 reduced CRC strength at the fastest time scales while increasing that at intermediate time scales, thus leaving the overall CRC strength unvaried; iii) despite exhibiting similar R rates and respiratory sinus arrhythmia, SB and CB15 induced different cardiorespiratory interactions; iv) no dominant temporal scheme was observed with relevant contributions of HP patterns either leading or lagging R. Discussion: LJSA is a useful methodology to explore HP-R dynamic interactions while accounting for time shifts and scales.

项与 CB-010 相关的新闻（医药）

2024-12-03

·PRNewswire

Lupus Nephritis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain

The lupus nephritis market is poised for growth, driven by rising disease prevalence, advancements in therapeutics such as biologics and targeted therapies, and increased investment in R&D. Heightened awareness and robust support from governments and key industry players further create a dynamic environment for innovation and better patient outcomes. LAS VEGAS, Dec. 3, 2024 /PRNewswire/ -- DelveInsight's ' Lupus Nephritis Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline lupus nephritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the lupus nephritis pipeline domain. Key Takeaways from the Lupus Nephritis Pipeline Report DelveInsight's lupus nephritis pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for lupus nephritis treatment. Key lupus nephritis companies such as AstraZeneca, Hoffmann-La Roche, Novartis, Qilu Pharmaceutical, Vera Therapeutics, Conduit Pharmaceuticals, Amgen, Johnson & Johnson, BeiGene, RemeGen, Argenx, Kyverna Therapeutics, Cabaletta Bio, ImmPACT Bio, Alpine Immune Sciences, AlloSite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, Adicet Bio, Shenzhen Pregene Biopharma Co., Ltd., Resolve Therapeutics, BioAegis Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, and others are evaluating new lupus nephritis drugs to improve the treatment landscape. Promising lupus nephritis pipeline therapies such as Anifrolumab, Obinutuzumab, Ianalumab, QLG1074, Atacicept, AZD1656, Daxdilimab, Nipocalimab, Zanubrutinib, Telitacicept, Efgartigimod alfa, KYV-101, CABA-201, IMPT-514, Povetacicept, ONT01, BCMA-CD19 cCAR T cells, CB-010, ADI-001, PRG-2311, RSLV-621, Recombinant human plasma gelsolin, LN-008, TST 008, and others are under different phases of lupus nephritis clinical trials. In November 2024, Adicet Bio announced that the first LN patient had been dosed in the Phase I clinical trial evaluating ADI-001 in autoimmune diseases. In November 2024, Kyverna Therapeutics announced that it would present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments. In October 2024, Kezar Life Sciences suspended subject enrolment and patient dosing in the Phase II PALIZADE trial of zetomipzomib for active lupus nephritis. In June 2024, Nkarta announced the initiation of Ntrust-I, a multi-center clinical trial of NKX019 in lupus nephritis, with the first patient in screening. The company also announced the clearance by the U.S. Food and Drug Administration (FDA) of its second Investigational New Drug (IND) application for NKX019 in autoimmune disease. In June 2024, Adicet Bio announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis. In April 2024, Caribou Biosciences announced that it had received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024. In March 2024, Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN). Request a sample and discover the recent advances in lupus nephritis treatment drugs @ Lupus Nephritis Pipeline Report The lupus nephritis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage lupus nephritis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the lupus nephritis clinical trial landscape. Lupus Nephritis Overview Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease that can affect multiple organ systems. In lupus nephritis, the immune system mistakenly attacks the kidneys, leading to inflammation and damage. The exact cause is not fully understood, but it is believed to involve a combination of genetic, hormonal, and environmental factors, including infections and exposure to certain drugs or UV light. Symptoms of lupus nephritis can vary but often include swelling in the legs and feet, high blood pressure, foamy urine, and in severe cases, hematuria. Patients may also experience fatigue, joint pain, and skin rashes, typical of lupus. Diagnosis usually involves a combination of blood tests, urinalysis, and imaging studies. A kidney biopsy may be necessary to evaluate the extent of kidney damage and guide treatment. Treatment for lupus nephritis aims to reduce inflammation and prevent kidney damage. It often involves corticosteroids and immunosuppressive medications such as mycophenolate mofetil or azathioprine. In severe cases, more aggressive treatments, including cyclophosphamide or biologic therapies like belimumab, may be utilized. Regular monitoring of kidney function and overall health is crucial for managing the disease effectively. Find out more about lupus nephritis treatment drugs @ Drugs for Lupus Nephritis Treatment A snapshot of the Lupus Nephritis Pipeline Drugs mentioned in the report: Learn more about the emerging lupus nephritis pipeline therapies @ Lupus Nephritis Clinical Trials Lupus Nephritis Therapeutics Assessment The lupus nephritis pipeline report proffers an integral view of the lupus nephritis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Lupus Nephritis Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Interferon alpha-beta receptor antagonists, Cell death inhibitors, Cell death stimulants, Antibody-dependent cell cytotoxicity, B-cell activation factor receptor antagonists, Glucokinase stimulants, Dendritic cell inhibitors, Complement factor D inhibitors, Complement C3 inhibitors, Proteasome inhibitors, Natural killer cell replacements, Immunologic cytotoxicity; T lymphocyte replacements Key Lupus Nephritis Companies: AstraZeneca, Hoffmann-La Roche, Novartis, Qilu Pharmaceutical, Vera Therapeutics, Conduit Pharmaceuticals, Amgen, Johnson & Johnson, BeiGene, RemeGen, Argenx, Kyverna Therapeutics, Cabaletta Bio, ImmPACT Bio, Alpine Immune Sciences, AlloSite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, Adicet Bio, Shenzhen Pregene Biopharma Co., Ltd., Resolve Therapeutics, BioAegis Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, and others. Key Lupus Nephritis Pipeline Therapies: Anifrolumab, Obinutuzumab, Ianalumab, QLG1074, Atacicept, AZD1656, Daxdilimab, Nipocalimab, Zanubrutinib, Telitacicept, Efgartigimod alfa, KYV-101, CABA-201, IMPT-514, Povetacicept, ONT01, BCMA-CD19 cCAR T cells, CB-010, ADI-001, PRG-2311, RSLV-621, Recombinant human plasma gelsolin, LN-008, TST 008, and others. Dive deep into rich insights for new drugs for lupus nephritis treatment, visit @ Lupus Nephritis Drugs Table of Contents For further information on the lupus nephritis pipeline therapeutics, reach out @ Lupus Nephritis Treatment Drugs Related Reports Lupus Nephritis Epidemiology Lupus Nephritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted lupus nephritis epidemiology in the 7MM. Lupus Nephritis Market Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including NOVARTIS, MORPHOSYS, ASTRAZENECA, ROCHE, KEZAR LIFE SCIENCES, ALEXION PHARMACEUTICALS, CABALETTA BIO, among others. Systemic Lupus Erythematosus Market Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies, including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others. Systemic Lupus Erythematosus Pipeline Systemic Lupus Erythematosus Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床申请

2024-12-03

·循因缉药

Senti|一支穿云箭，4500万

环球视野，深度视角各位亲爱的股东，大家早上好中午好晚上好。真的好久没关注Senti Biosciences了。这次多亏是我们亲爱的股东提醒：Senti，发了！扫了一眼，确实。我仔细数了数，盘前暴涨231%~横竖睡不着觉啊~ 没赚到比亏钱了还难受...泪目了。开个玩笑哈，大家知道我这样的穷人是不碰股票的。为啥，因为已经亏光了... 那么Senti Biosciences的上涨到底为啥？ #01 2/3完全缓解 2024年12月2日，Senti Bio宣布了该公司候选药物SENTI-202初步的I期临床结果： 2/3的患者取得了完全缓解（CR）！该款药物为“现货型”CAR-NK细胞疗法产品，适应症为复发难治血液瘤包括AML、MDS等。第一，SENTI-202通过双价CD33和/或FLT3靶向潜在的深度和持久反应; 第二，通过在健康造血干细胞（HSCs）上特有表达的内皮素（EMCN）保护抗原提供潜在的改善安全性和增加治疗窗口; 第三，校准释放IL-15：潜在增加细胞扩增、持续性和杀伤肿瘤的能力。 SENTI-202引入“细胞电路”概念，通过独有的逻辑门技术，旨在克服AML的疾病异质性。合成万物，创造新生|Senti-把细胞编程为听话的机器人想要了解Senti的可以看看我们之前的文章，呃，这不是重点。重点是，这个临床结果有点厉害了。在每次输注10亿CAR-NK细胞后3个周期后，参与临床的3例患者出现了2例CR（Complete Remission，完全缓解）。这还不算什么，这两例患者还是MRD（measurable residual disease，微小残留病灶）阴性，也就是说齐潜在获益可能更优、复发可能性更低。于是乎...芜湖起飞~ Senti 一飞冲天，甚至盘中出现熔断。冷知识：美国个股虽然没涨跌停限制，但是也熔断。 Senti的市值也达到5589万美元，还记得一开始的数字么？不到1000万美元。好家伙，这一支穿云箭直接干下来4500万美元！！！但是，这里要说但是了。个人认为，现在就开香槟庆祝还是早了点。 #02 半场香槟这里有3个问题需要注意。第一，目前的患者人数还不足以完全代表疗效。大家都知道，细胞治疗在入组人数少的时候跟扩大样本量之后的结果相比较往往存在较大出入。比如，曾经的Caribou CB-010也拿下过100%的ORR和80%的CR。最终结果也并不见得尽如人意，还被人家告了要赔钱。第二，副作用需要关注。值得关注的是，本次披露的3例患者均出现了4级血液学毒性反应。当然，这是由于治疗前期的“清淋”造成的。我们说的是后续的其他副作用需要关注，比如CRS啊、持续性的血细胞减少等等。本次报道的3里患者有2例出现了CRS（细胞因子释放风暴），略高于CB-010的水平。还是那句话，这也可能是入组受试者不足造成的。第三，SENTI-202的市场潜力尚存不确定性。不管是市场容量、竞争格局都不是那种爽文主角，还需要看市场推广情况、支付情况等等。因此，半场香槟可是大忌啊。在回过味来之后，Senti的股价也出现了回落。最终以10美元/股报收，呃，16块冲进去的哥们要相信价值投资。至少，短时间内Senti还挂不了。 #03 续命其实，对Senti来说当天另一条消息可能更为重要。当天，Senti宣布拿到了来自Celadon领投的3760万美元的私募股权融资，司与现有和新的合格投资者签订了证券购买协议，通过私募股权投资（PIPE）融资方式发行和出售了16713股A系列可转换优先股（"优先股"）。要知道，在2024Q3公布的财报中，Senti账上的现金仅剩1586万美元。而当季亏损高达1120.3万美元，眼瞅就撑不下去了。所以，你说这3760万美元重要不重要？经此，Senti在2025年Q3之前没有作的话大概率活下来没问题。 #04 最后大家有没有好奇Senti这次用的MRD是哪家的产品啊？反正我是挺好奇的。找了半天，能确定的是2例患者1例使用了NGS技术进行MRD状态监控，另外一例使用流式进行MRD监控。我们的老朋友、另外一家“现货型”细胞治疗公司Allogene的ALPHA3 II期临床也用了MRD检测技术。 Allogene明确告诉大家他们用的是FORESIGHT CLARITY，你看，多大方。最后的最后，再次提醒大家投资需谨慎。哦，Senti还将继续推进SENTI-202的临床试验，15亿细胞的cohort也将启动。我们拭目以待。 END 啊对对对对，扫描这货能联系到我至此，各位股东星标了么？点赞了么？转发了么？在看了么？谢谢！所有内容均不作为投资建议，信息均来自公开资料。近期文章：国产测序仪风云录|院士领衔的孔确基因纳米孔测序 Caribou Bio 390万美元买个清净 Cologuard 2.0：我们的医保很有钱呀目标50000例！纳米孔表观测序项目启动！ Guardant Health等来的正义：2.925亿美元蛋白测序明星裁员23% 相关资料：注1：https://investors.sentibio.com/news-releases/news-release-details/senti-bio-announces-positive-initial-clinical-data-phase-1注2：https://investors.sentibio.com/news-releases/news-release-details/senti-biosciences-inc-announces-oversubscribed-376-million

细胞疗法临床1期免疫疗法临床结果

2024-11-28

·循因缉药

Caribou Bio 390万美元买个清净

环球视野，深度视角各位亲爱的股东，大家早上好中午好晚上好。最近都在忙着看财报，竟然漏了Caribou Biosciences。呃，其实也不算，在没有产品上市之前，这些biotech的财报其实最大的作用是看能活多久。只要帐上现金还有、能“忽悠”到接盘侠，也没必要经常去看。不过，最近Caribou 还是有点“花活”值得关注的。其中，一个引子就是一项集体诉讼可能要了结了。 #01 律师费109万美元 2024年11月18日，就在这个吉祥的日子（18=要发），美国一家律所 The Rosen Law Firm（下称Rosen）发布了一份公告。美国加利福尼亚北区地方法院批准了一项拟议的集体诉讼和解，2021年7月23日至2023年7月13日期间购买Caribou Biosciences的朋友们可以申请赔偿了。呃，2021年7月23日就是Caribou上市首日，假设当天买入的话到2023年7月13日也就亏了不到60%。就...还好吧。听证会定于2025年2月18日下午1:30在加利福尼亚北区地方法院举行，主要为了以下3件事：第一，是否批准包括390万美元在内的和解提案；第二，是否批准和解金分配计划；第三，是否批准首席律师申请的律师费（不超过和解金额的28%，即109.2万美元）、不超过6万美元的费用报销，以及原告代表和解类别的合理成本和费用补偿（包括工资损失）不超过7500美元；所以，美国为啥律师算高薪职业呢？那么，Caribou到底是犯了什么天条？Rosen又是哪颗葱？ #02 祸起CB-010 CB-010我们是非常熟悉了，靶向CD19的 CAR-T疗法。通过敲除TRAC基因（T细胞受体α恒定区），T细胞表面的T细胞受体（TCR）被清除，可避免移植物抗宿主反应（GvHD），敲除编码PD-1的基因，提高CAR-T细胞抗肿瘤活性的持久性。因此，这是一款创新的用于治疗B细胞非霍奇金淋巴瘤的“现货型”细胞疗法。在上市之时，CB-010是进展最快的项目，已经开展一期临床试验。那Rosen为啥要告Caribou呢？有2点：第一，CB-010的有效性并不像Caribou宣传的那么拔群；第二，CB-010的商业化前景也被Caribou夸大了；我们先看第二条。商业化前景我们大概之前聊过一些，CD19的细胞治疗实在是太多太多了。比如自体的Kymriah、Yescarta、Tecartus等都是靶向CD19，“现货型”也有来自Allogne的cema-cel，CRISPR的CTX112等等。当然，这不重要，商业化这事属于魔法范畴。最致命的是对CB-010有效性的攻击。在2022年5月份的临床试验更新中，CB-010取得了100%的ORR（客观缓解率）和80%的CR（完全缓解）。 2024年6月份的数据更新中，ORR已经被干到了76%，CR剩下了46%。你说，这算疗效不好、存在欺诈吗？似乎也不算，基于当时的数据他就是好的，基于目前的数据他就是没有那么拔群的。 Caribou又从HLA分型上进行了找补，部分匹配的患者ORR明显提升。而且，CB-010还计划开红斑狼疮适应症的临床。 2024年9月，FDA授予了CB-010快速通道认定。所以，似乎也没那么糟糕。但是，有个集体诉讼老挂在那里聒噪，也不能算个好事。这390万美元，就是买个清净啊。 #03 最后最后说一嘴Rosen。 Rosen据说是全美排名第四的证券集体诉讼律所，2019年为投资者挽回超4.38亿美元的损失。 Rosen采用完全风险代理费模式，意味着客户无需预付费用，只有在成功追回资金后才收取一定比例的费用。当然，这种模式收费一般比较高。比如，今天提到的这次诉讼，有很大一部分（最多28%）归律所所有。他们影响力最大的一次胜利应该是阿里巴巴案。 2014年7月16日，当时，中国国国家工商总局网监司在浙江召开阿里巴巴行政指导座谈会，并根据座谈情况形成了《关于对阿里巴巴集团进行行政指导工作情况的白皮书》。该白皮书列出了阿里巴巴存在的一些问题，如销售侵权商品、不合格商品和假冒伪劣产品等。后来，国家工商总局公布该白皮书后，阿里巴巴股票在2015年1月28日和29日下跌了12.8%。对此，一些西方媒体认为阿里巴巴在美国上市(2014年9月)前存在信息披露不到位的情况。最终，和解金额达到惊人的2.5亿美元，Rosen作为独家法律法律代理最多可以分到其中的25%。呃，也就是大约6000万美元。后悔啊，所有的生物人给我进来哭... 哦，对了，顺带插播一个最新消息： 2024年11 月 27 日，艺妙神州宣布，公司首款自主研发的靶向 CD19 的自体 CAR-T 细胞候选产品 IM19 嵌合抗原受体 T 细胞注射液（IM19）上市申请获 NMPA 受理，用于治疗复发或难治弥漫大 B 细胞淋巴瘤（r/r DLBCL）。 END 啊对对对对，扫描这货能联系到我至此，各位股东星标了么？点赞了么？转发了么？在看了么？谢谢！所有内容均不作为投资建议，信息均来自公开资料。近期文章： Cologuard 2.0：我们的医保很有钱呀目标50000例！纳米孔表观测序项目启动！ Guardant Health等来的正义：2.925亿美元蛋白测序明星裁员23% 安捷伦Agilent事业群重磅重组！ Twist：拜托了，总统先生相关资料：注1：https://www.globenewswire.com/news-release/2024/11/18/2982748/673/en/The-Rosen-Law-Firm-P-A-Announces-Proposed-Class-Action-Settlement-on-Behalf-of-Purchasers-of-Common-Stock-of-Caribou-Biosciences-Inc-CRBU.html注2：https://www.prnewswire.com/news-releases/crbu-investor-notice-rosen-a-leading-national-firm-encourages-caribou-biosciences-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action--crbu-301746820.html注3：https://rosenlegal.com/case/caribou-biosciences-inc/注4：https://investor.cariboubio.com/static-files/7f40ddd9-0b0a-4d1f-80ef-9d3768aeaec6

财报基因疗法细胞疗法免疫疗法临床1期

100 项与 CB-010 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性B细胞淋巴瘤	临床1期	美国	Caribou Biosciences, Inc.	2021-05-26
难治性B细胞淋巴瘤	临床1期	澳大利亚	Caribou Biosciences, Inc.	2021-05-26
难治性B细胞淋巴瘤	临床1期	以色列	Caribou Biosciences, Inc.	2021-05-26
复发性非霍奇金淋巴瘤	临床1期	美国	Caribou Biosciences, Inc.	2021-05-26
复发性非霍奇金淋巴瘤	临床1期	澳大利亚	Caribou Biosciences, Inc.	2021-05-26
复发性非霍奇金淋巴瘤	临床1期	以色列	Caribou Biosciences, Inc.	2021-05-26
肾外狼疮	临床1期	美国	Caribou Biosciences, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04637763 (ANTLER, ASCO2024) 人工标引	临床1期	B细胞淋巴瘤	16	CB-010 at 40 x 106 CAR-T cells	範積繭獵構積窪構範壓(鹽淵醖淵範夢鏇範遞蓋) = Not seen. 鑰鹹築壓艱願繭鑰壓鬱 (遞構簾鏇選鬱遞鬱製膚 ) 更多	积极	2024-05-24
				CB-010 at 80 x 106 CAR-T cells
NCT04637763 (ANTLER, EHA 12024 \| EHA 22024) 人工标引	临床1期	非霍奇金淋巴瘤	16	CB-010	顧鹽鹹醖鹹願遞鏇獵夢(壓製簾衊淵窪糧夢遞積) = 製鹹鑰網願積繭獵廠繭鏇鏇製鑰獵選遞築簾繭 (範鏇夢簾窪齋顧範構淵 ) 更多	积极	2024-05-14
				CB-010 (LBCL)	顧鹽鹹醖鹹願遞鏇獵夢(壓製簾衊淵窪糧夢遞積) = 壓衊夢醖觸憲艱夢醖衊鏇鏇製鑰獵選遞築簾繭 (範鏇夢簾窪齋顧範構淵 ) 更多
NCT04637763 (ANTLER, Corporate Publications) 人工标引	临床1期	难治性B细胞淋巴瘤	6	CB-010	艱齋網憲網願範壓遞廠(構衊膚窪鹽鑰醖積糧選) = 40x10^6 CAR-T cells（grade 1 CRS 33% and grade 3 ICANS 17%）願夢範夢鹽憲壓衊範憲 (廠艱襯顧鑰繭鏇淵淵鏇 )	积极	2022-06-10